Bristol Myers Squibb stock gains support from positive Sotyktu data and higher analyst targets

Bristol Myers Squibb Company stock (ISIN US1101221083) is drawing renewed investor attention after the company reported positive two-year Phase 3 data for its psoriasis drug Sotyktu on September 17, 2026, while analysts such as Piper Sandler have recently raised their price targets on the shares.

Positive two-year Sotyktu data as fresh catalyst

On September 17, 2026, Bristol Myers Squibb announced positive results from the Phase 3 POETYK PsA-2 study, including its open-label extension, showing durable efficacy and a consistent safety profile for Sotyktu (deucravacitinib) in adults with active psoriatic arthritis, according to Bristol Myers Squibb.

The same development is highlighted as the most recent FDA-related event for Bristol Myers Squibb and categorized as positive results, with the company emphasizing durable efficacy over two years of treatment in psoriatic arthritis patients, as noted by MarketBeat on September 17, 2026.

For investors, the positive Sotyktu data strengthens Bristol Myers Squibb's immunology and inflammation franchise and supports expectations for continued revenue contributions from newer therapies, even though detailed revenue or margin figures for this study were not disclosed in these updates.

Dividend, valuation and target price moves

The stock's income profile remains a key part of the investment case. On September 16, 2026, a dividend-focused overview underscored that Bristol Myers Squibb offers a dividend yield of 3.95 percent with a payout ratio of 39 percent and a three-year dividend growth rate of 4.4 percent, suggesting the dividend is sustainable, according to GuruFocus.

The same analysis puts Bristol Myers Squibb's GF Value, an intrinsic value estimate, at USD 56.60, while the shares were cited at a current stock price of USD 63.60, implying the stock trades about 12.4 percent above that valuation benchmark as of September 17, 2026, according to GuruFocus.

Analyst sentiment has nudged higher. On September 16, 2026, Piper Sandler analyst David Amsellem reiterated an Overweight rating on Bristol Myers Squibb and raised his price target from USD 75.00 to USD 82.00, a 9.33 percent increase in the valuation he applies to the stock, as reported by GuruFocus.

Alongside Piper Sandler, other brokers have also been constructive. A recent analyst overview notes one Strong Buy rating, thirteen Buy ratings, ten Hold ratings and one Sell rating, leading to an average rating of Moderate Buy and an average target price of USD 66.72 for Bristol Myers Squibb shares, according to MarketBeat on September 16, 2026.

The stock's valuation metrics reflect this cautiously positive stance. One recent overview cites a trailing twelve month price-earnings ratio of about 14 times, below Bristol Myers Squibb's five-year median P/E of roughly 18 times, suggesting that while the shares appear modestly overvalued relative to one intrinsic value model, they trade at a discount versus their own historical earnings multiple, according to GuruFocus.

Dividend timeline and broader cash flow context

Bristol Myers Squibb's dividend policy remains in focus for income-oriented investors. A recent dividend alert notes that the company has declared a quarterly dividend of USD 0.63 per share, implying an annual dividend of USD 2.52 per share, and that analysts expect the company to earn USD 6.44 per share next year, which would keep the forward payout ratio near 39.1 percent, according to MarketBeat on September 16, 2026.

The ex-dividend date for this USD 0.63 payment has been set for October 2, 2026, with the distribution scheduled for November 2, 2026, giving current shareholders a clear timeline for the next cash return, as highlighted by Futunn News.

Cash generation supports this policy. A discounted cash flow-based assessment cites Bristol Myers Squibb's trailing twelve month free cash flow at about USD 11.5 billion, with modeled future annual free cash flows expected in a similar USD 10 billion to USD 13 billion range, providing a substantial base for dividends and potential share repurchases, according to Simply Wall St on September 17, 2026.

This cash flow profile underpins the company's capacity to fund research and development for assets like Sotyktu while continuing to serve as a steady dividend payer, a combination that many long-term holders regard as central to Bristol Myers Squibb stock's appeal.

Risks from pipeline pruning and macro backdrop

Despite the positive Sotyktu update, Bristol Myers Squibb continues to refine its pipeline, and not all development programs move forward. On September 17, 2026, Orum Therapeutics disclosed that Bristol Myers Squibb had returned ORM-6151, a degrader-antibody conjugate candidate for blood cancer that had been licensed in 2023, following a decision to discontinue development after Phase 1 trials in the United States, Europe and Canada, resulting in the cancellation of up to USD 80 million in potential milestone payments, according to Seoul Economic Daily.

For Bristol Myers Squibb stock, such decisions illustrate the typical risk profile of large biopharmaceutical companies, where promising assets may still be terminated based on trial data, and where future growth depends on successfully advancing a mix of late-stage and early-stage programs.

The broader market environment also influences the shares. A recent macro report notes that major United States stock indices declined after a hawkish rate hike by the Federal Reserve, with the Dow Jones Industrial Average down 1.3 percent, the S&P 500 down 0.69 percent and the Nasdaq Composite off 0.37 percent as of mid-September 2026, indicating a cautious backdrop for equities, including healthcare names such as Bristol Myers Squibb, according to Moneycontrol.

Investors will therefore weigh the supportive factors from Sotyktu data, dividend sustainability and analyst upgrades against ongoing pipeline risks and a more demanding interest-rate climate when assessing Bristol Myers Squibb stock at current levels.

Stock price level and trading context

Recent price data place Bristol Myers Squibb shares in the low USD 60s on their primary listing. An FDA event overview shows the stock at a closing price of USD 63.54 with a daily decline of 0.29 percent, or USD 0.19, as of September 16, 2026 at 3:59 p.m. Eastern Time on the New York Stock Exchange, and an extended trading indication of USD 63.68, up USD 0.13 or 0.21 percent in early pre-market trading on the following session, according to MarketBeat.

A valuation snapshot taken on September 17, 2026 cites the Bristol Myers Squibb stock price at USD 63.60 versus a GF Value estimate of USD 56.60, indicating the shares were trading about 12.4 percent above that intrinsic value measure at that time, according to GuruFocus.

For investors, the combination of a USD 63.54 to USD 63.60 share price range as of September 16-17, 2026, a dividend yield close to 4 percent and a price level moderately above one intrinsic value benchmark but below the raised USD 82.00 Piper Sandler target provides a concise snapshot of Bristol Myers Squibb stock's current trading context on the New York Stock Exchange.

More news and analyses on Bristol Myers Squibb stock